Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (253)	2/24/1999 12:40:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1127

Thanks PB. I was aware of VEGF-B and VEGF-C (only patent on VEGF-B). So, picture may be bit more complicated than we think. ncbi.nlm.nih.gov It looks like similar story on Angio-1,-2 and -3, where overlaping and cross-interaction (combination of positive and negative regulation) complicate things. Ar least, it appears that all VEGFs bind to the same receptors with bit different affinity. BTW, I do not see that VEGF-2 (from HGSI) may be better than other VEGF forms. Miljenko